在获得突破性的长期房颤治疗临床数据后,Pulse Biosciences宣布进行战略重组,将集中资源全力推进其心脏导管项目的研发进程。这一决策基于最新临床研究显示的持久疗效,有望为心律失常治疗领域带来革新性进展。
在获得突破性的长期房颤治疗临床数据后,Pulse Biosciences宣布进行战略重组,将集中资源全力推进其心脏导管项目的研发进程。这一决策基于最新临床研究显示的持久疗效,有望为心律失常治疗领域带来革新性进展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.